Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
IL-6-based mortality risk model for hospitalized patients with COVID-19.
Laguna-Goya R; Utrero-Rico A; Talayero P; Lasa-Lazaro M; Ramirez-Fernandez A; Naranjo L; Segura-Tudela A; Cabrera-Marante O; Rodriguez de Frias E; Garcia-Garcia R; Fernández-Ruiz M; Aguado JM; Martinez-Lopez J; Lopez EA; Catalan M; Serrano A; Paz-Artal E.
J Allergy Clin Immunol
(Unknown)
Published: 2020
Successful use of methylprednisolone for treating severe COVID-19.
J Allergy Clin Immunol
(Unknown)
Published: 2020
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized control…
Cao Y; Wei J; Zou L; Jiang T; Wang G; Chen L; Huang L; Meng F; Huang L; Wang N; Zhou X; Luo H; Mao Z; Chen X; Xie J; Liu J; Cheng H; Zhao J; Huang G; Wang W; Zhou J.
J Allergy Clin Immunol
(Unknown)
Published: 2020
Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China.
Chen R; Sang L; Jiang M; Yang Z; Jia N; Fu W; Xie J; Guan W; Liang W; Ni Z; Hu Y; Liu L; Shan H; Lei C; Peng Y; Wei L; Liu Y; Hu Y; Peng P; Wang J; Liu J; Chen Z; Li G; Zheng Z; Qiu S; Luo J; Ye C; Zhu S; Zheng J; Zhang N; Li Y; He J; Li J; Li S; Zhong N; Medical Treatment Expert Group for COVID-19.
J Allergy Clin Immunol
(Unknown)
Published: 2020
Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.
Yang Y; Shen C; Li J; Yuan J; Wei J; Huang F; Wang F; Li G; Li Y; Xing L; Peng L; Yang M; Cao M; Zheng H; Wu W; Zou R; Li D; Xu Z; Wang H; Zhang M; Zhang Z; Gao GF; Jiang C; Liu L; Liu Y.
J Allergy Clin Immunol
(Unknown)
Published: 2020